Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Invested Capital (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Invested Capital for 7 consecutive years, with $1.9 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Invested Capital fell 98.17% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Sep 2019, down 98.17%, and an annual FY2018 reading of $2.9 million, down 96.27% over the prior year.
  • Invested Capital was $1.9 million for Q3 2019 at Larimar Therapeutics, up from $543000.0 in the prior quarter.
  • Across five years, Invested Capital topped out at $221.7 million in Q1 2015 and bottomed at $543000.0 in Q2 2019.
  • Average Invested Capital over 5 years is $102.1 million, with a median of $103.9 million recorded in 2018.
  • The sharpest move saw Invested Capital skyrocketed 70.6% in 2015, then tumbled 98.96% in 2019.
  • Year by year, Invested Capital stood at $169.1 million in 2015, then decreased by 28.02% to $121.7 million in 2016, then crashed by 35.74% to $78.2 million in 2017, then plummeted by 96.27% to $2.9 million in 2018, then tumbled by 34.9% to $1.9 million in 2019.
  • Business Quant data shows Invested Capital for LRMR at $1.9 million in Q3 2019, $543000.0 in Q2 2019, and $1.2 million in Q1 2019.